We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    SING IMT
Previous Study | Return to List | Next Study

Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD (CONCERTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05438732
Recruitment Status : Recruiting
First Posted : June 30, 2022
Last Update Posted : March 29, 2023
ORA, Inc.
Information provided by (Responsible Party):
VisionCare, Inc.

Brief Summary:
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Age-Related Macular Degeneration Geographic Atrophy Device: smaller incision, new generation implantable miniature telescope (SING-IMT) Not Applicable

Detailed Description:
Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study, including assessment of their best-corrected distance- and near- visual acuity with and without refraction, and also when using an external telescope simulator (ETS) to determine if they are likely to benefit from receiving the IMT. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery. Following implantation, patients will return for 5 post-operative follow-up visits over a period of approximately 12 months. Additionally, patients will have up to 12 rehabilitation/training visits with a low vision specialist

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Effectiveness: one-sided asymptotic normal test Safety: one-sided t-test
Masking: None (Open Label)
Masking Description: since the IMT has a unique appearance in the eye, it cannot be masked to the Investigator or to the patient
Primary Purpose: Other
Official Title: A Prospective, Multicenter Clinical Study of the Implantable Miniature Telescope, Model SING in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration (AMD)
Actual Study Start Date : June 16, 2022
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SING-IMT Implanted
the implanted eye will be the study eye which receives the SING-IMT. Implantation will occur during routine cataract surgery using a proprietary delivery system (loading cartridge and injector), via an approximately 6.5mm incision
Device: smaller incision, new generation implantable miniature telescope (SING-IMT)
The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)

Primary Outcome Measures :
  1. Primary Effectiveness Outcome [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    Proportion of study eyes with an improvement of 10 or more ETDRS letters (0.2 logMAR) in either BCDVA or BCNVA at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit

  2. Primary Safety Outcome [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    Percent change in endothelial cell density (ECD) from Pre-operative Visit in study eyes at Visit 5 (330 to 420 days post-operatively)

Secondary Outcome Measures :
  1. Best-corrected distance visual acuity (BCDVA) [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    Post-operative BCDVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit

  2. Best-corrected near visual acuity (BCNVA) [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    Post-operative BCNVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit

  3. Anterior Chamber Depth [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    Anterior Chamber Depth in study eyes, defined as the distance between the corneal endothelium and the front surface of the IMT, at Visit 5 (330 to 420 days post-operatively)

  4. IMT position [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    IMT tilt and centration in study eyes at Visit 5 (330 to 420 days post-operatively)

  5. Adverse Events [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    Rates of adverse events from Operative Visit through Visit 5 (330 to 420 days post-operatively)

  6. Posterior Capsule Opacification [ Time Frame: Approximately 12-months post-operatively (330-420 days) ]
    Rates of posterior capsule opacification in study eyes at post-operative visit 5 (330 to 420 days post-operatively)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be at least 65 years of age at the Pre-operative Visit;
  2. Have ETDRS BCDVA 0.9 to 1.6 logMAR (20/160 to 20/800) at the Pre-operative Visit caused by bilateral central scotomas associated with end-stage AMD;
  3. Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by standard of care fluorescein angiography (FA) prior to the Pre-operative Visit;
  4. Have been monitored by an eye care professional over the 6-month (or longer) period immediately prior to the Pre-operative Visit and have demonstrated no evidence of active choroidal neovascularization (CNV) prior to the Pre-operative Visit as demonstrated by the following:

    1. lack of need of treatment for CNV over the past 6 months, and
    2. lack of active exudative fluid on optical coherence tomography (OCT) over the past 6 months, and
    3. lack of Retinal hemorrhage on exam over a 6-month period or longer
  5. Agree to participate in post-operative visual training

    For the Implanted Eye:

  6. Have evidence of visually significant cataract at the Pre-operative Visit;
  7. Agree to undergo pre-operative training and assessment (1 or more sessions) with low vision specialists (optometrist or occupational therapist) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment

    For the Non-Implanted Eye:

  8. Have adequate peripheral vision at the Pre-operative Visit to allow navigation

Exclusion Criteria:

  1. Have cognitive impairment that would interfere with the ability to understand and provide Informed Consent or prevent proper visual training/rehabilitation with the device;
  2. Have any of the following conditions at the Pre-operative Visit:

    1. Stargardt macular dystrophy;
    2. Diabetic retinopathy;
    3. Untreated retinal tears;
    4. Retinal vascular disease;
    5. Optic nerve disease;
    6. History of retinal detachment;
    7. Intraocular tumor;
    8. Retinitis pigmentosa;
  3. History of steroid-induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP >22 mmHg at the Pre-operative Visit;
  4. Have known allergy to post-operative medications;
  5. History of eye rubbing or an ocular condition that predisposes subject to eye rubbing;
  6. Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit;
  7. Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety;
  8. Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study;
  9. Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit

    For the Implanted Eye:

  10. Have central anterior chamber depth (ACD) <3.0 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit;
  11. Have an Endothelial Cell Density (ECD) below:

    1. 2,000 cells per millimeter, if 65-84 years old;
    2. 1,800 cells per millimeter, if 85 years old or greater (based on the lowest value of the three cell counts performed by technician at investigative site at the Pre-operative Visit)
  12. Have a history of corneal stromal or endothelial dystrophies, including guttata;
  13. Have Myopia > 6.0 D or Hyperopia > 4.0 D by Manifest Refraction at the Pre-operative Visit;
  14. Have an Axial Length (AL) < 21 mm at the Pre-operative Visit;
  15. Have a narrow angle defined as < grade 2 on the Schaffer scale at the Pre-operative Visit;
  16. Ongoing Inflammatory ocular disease at the Pre-operative Visit;
  17. Zonular weakness/instability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit;
  18. Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery;
  19. Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes;

    For the Non-Implanted Eye:

  20. Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05438732

Layout table for location contacts
Contact: Rebecca Kammer, OD, PhD +1 (714) 728-1575 rkammer@samsaravision.com
Contact: Jennifer Adams, PhD, RN +1 (858) 344-3250 jadams@oraclinical.com

Layout table for location information
United States, California
Loma Linda University Recruiting
Loma Linda, California, United States, 92354
Contact: Rebecca Pereyra, BS       rpereyra@llu.edu   
Contact: Norlisha Borntrager, BS       NBorntrager@llu.edu   
Principal Investigator: Michael Rauser, MD         
California Eye Specialists Recruiting
Pasadena, California, United States, 91107
United States, Florida
Sarasota Retina Institute Recruiting
Sarasota, Florida, United States, 34239
United States, Massachusetts
Tallman Eye Associates Recruiting
Lawrence, Massachusetts, United States, 01843
United States, New Jersey
Atlantic Eye Surgery Center Recruiting
Eatontown, New Jersey, United States, 07724
Laser Vision Correction Center Recruiting
Whippany, New Jersey, United States, 07981
United States, North Carolina
Asheville Eye Associates Recruiting
Asheville, North Carolina, United States, 28803
United States, Pennsylvania
Erie Retinal Surgery Recruiting
Erie, Pennsylvania, United States, 16507
United States, Texas
Texas Retina Center Recruiting
Houston, Texas, United States, 77030
United States, Wisconsin
University Station Clinic Recruiting
Madison, Wisconsin, United States, 53705
Sponsors and Collaborators
VisionCare, Inc.
ORA, Inc.
Layout table for investigator information
Study Director: Rebecca J Kammer, OD, PhD Samsara Vision Inc.
Layout table for additonal information
Responsible Party: VisionCare, Inc.
ClinicalTrials.gov Identifier: NCT05438732    
Other Study ID Numbers: CDV-SNG-21-001
First Posted: June 30, 2022    Key Record Dates
Last Update Posted: March 29, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by VisionCare, Inc.:
best-corrected distance visual acuity
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases